Nasdaq auph.
Dec 4, 2023 · Shares of NASDAQ AUPH opened at $9.06 on Monday. The company has a current ratio of 5.77, a quick ratio of 5.33 and a debt-to-equity ratio of 0.18. Aurinia Pharmaceuticals Inc. has a twelve month low of $4.07 and a twelve month high of $12.43. The stock has a 50 day moving average of $7.93 and a two-hundred day moving average of $9.20.
Nov 27, 2023 · Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement ... If you’re familiar with investing, then you’ve probably heard of major stock exchanges like the New York Stock Exchange or the NASDAQ. Stock exchanges are sort of like a mixture between an auction house and a marketplace where investors can...Agios Pharmaceuticals (NASDAQ:AGIO) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, community ranking, dividends, valuation, media sentiment, analyst recommendations and institutional ...December 4, 2023. Technologies. Vertex Energy Inc (NASDAQ:VTNR) has a beta value of 1.68 and has seen 0.54 million shares traded in the recent trading session. The company, currently valued at $348.79M, closed the recent trade at $3.73 per share which meant it gained $0.11 on the day or 3.04% during that session.Aurinia Pharmaceuticals (NASDAQ:AUPH) could see prices in the high $20s to low $30s per share in a takeout at premium multiples, according to RBC, after the company announced Thursday it was ...
Aurinia Pharmaceuticals (NASDAQ:AUPH) could see prices in the high $20s to low $30s per share in a takeout at premium multiples, according to RBC, after the company announced Thursday it was ...
View the latest Aurinia Pharmaceuticals Inc. (AUPH) stock price, news, historical charts, analyst ratings and financial information from WSJ.
June 30, 2023 — 02:07 pm EDT. Below is Validea's guru fundamental report for AURINIA PHARMACEUTICALS INC ( AUPH). Of the 22 guru strategies we follow, AUPH rates highest using our Value Investor ...Dec 4, 2023 · AUPH Earnings Date and Information. Aurinia Pharmaceuticals last issued its quarterly earnings data on November 2nd, 2023. The biotechnology company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.08. The company had revenue of $54.52 million for the quarter, compared to the consensus estimate of $38 ... Find the latest Financials data for Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) at Nasdaq.com.View live Aurinia Pharmaceuticals Inc chart to track its stock's price action. Find market predictions, AUPH financials and market news.
AUPH Earnings Date and Information. Aurinia Pharmaceuticals last released its quarterly earnings results on November 2nd, 2023. The biotechnology company …
Aurinia Pharmaceuticals (NASDAQ:AUPH) is a biopharmaceutical firm delivering therapies for autoimmune, kidney, and rare diseases with unmet medical …
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH): Supportive interim analysis of its AURORA 2 Phase 3 continuation study that is evaluating Lupkynis for the treatment of lupus nephritis.Price. 9.04. Webull offers AUPH Ent Holdg (AUPH) historical stock prices, in-depth market analysis, NASDAQ: AUPH real-time stock quote data, in-depth charts, free AUPH …Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) Q3 2023 Earnings Call Transcript November 2, 2023 Aurinia Pharmaceuticals Inc. beats earnings expectations. …VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for third ...To find the current corn price per bushel, there are a number of websites and places to look for predictions about the commodities market. Corn prices are listed on sites like NASDAQ and AgWeb if you want a quick answer.Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest ...
Nov 29, 2023 · The average twelve-month price prediction for Aurinia Pharmaceuticals is $14.00 with a high price target of $15.00 and a low price target of $13.00. Learn more on AUPH's analyst rating history. Do Wall Street analysts like Aurinia Pharmaceuticals more than its competitors? About Latest Pre-Market Trades. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.The new research reports from Fundamental Markets, available for free download at the links above, examine B Communications Ltd. (NASDAQ:BCOM), Student Transportation Inc (NASDAQ:STB), Aurinia ...Noteworthy Friday Option Activity: W, ON, AUPH. July 28, 2023 — 04:50 pm EDT. Written by BNK Invest for BNK Invest ->. Looking at options trading activity among components of the Russell 3000 ...The new research reports from Capital Review, available for free download at the links above, examine Adverum Biotechnologies, Inc. (NASDAQ:ADVM), Aurinia Pharmaceuticals Inc (NASDAQ:AUPH), Baytex ...Aurinia Pharmaceuticals AUPH stock was up about 11% on Tuesday after the company announced that the United States Patent and Trademark Office (USPTO) issued a new and refined method-of-use patent ...NASDAQ: AUPH Aurinia Pharmaceuticals. Market Cap. $1B. Today's Change (2.09%) $0.18. Current Price. ... (AUPH 2.09%) rose by as much as 13.2% in early morning trading Friday. The biotech's shares ...
Caiaimage/Paul Bradbury. Aurinia Pharmaceuticals ( NASDAQ: AUPH) has begun to examine strategic alternatives that could include a potential sale or merger. The pharma has retained JP Morgan as ...Aurinia Pharmaceuticals ( NASDAQ: AUPH) has been on a roll this year since their second quarter earnings in August. The stock jumped from $10 to over $30, buoyed by strong uptake of voclosporin ...
AUPH closed Tuesday's trading at $16.05, up 4.09%. ... views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has added two assets to expand its rare autoimmune and kidney-related disease pipeline. The first program, AUR200, was acquired from privately-held ...Shares of Aurinia Pharmaceuticals Inc. AUPH gained 13.2% on Dec 2, following fresh rumors of a potential buyout. Reportedly, Swiss pharma giant Novartis NVS is looking out for small bolt-on ...Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today provided an update on its business performance. Preliminary unaudited net revenue for the three months and full year ...Aurinia Pharmaceuticals ( AUPH 3.43%), a small-cap commercial-stage drugmaker, is having another strong session today. Specifically, the biotech's stock was up by 11.9% on moderate volumes as of 1 ...Aurinia Pharmaceuticals Price Performance Shares of NASDAQ:AUPH opened at $9.06 on Monday. Aurinia Pharmaceuticals Inc. has a twelve month low of …Based on analysts offering 12 month price targets for AUPH in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . Below is a chart showing AUPH's trailing twelve month trading history, with the $9 strike highlighted in orange: Phillips 66 (Symbol: PSX) options are showing a volume of 21,547 contracts thus far ...Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has added two assets to expand its rare autoimmune and kidney-related disease pipeline. The first program, AUR200, was acquired from privately-held ...Canadian biotech Aurinia Pharmaceuticals ( NASDAQ: AUPH) jumped ~11% pre-market Wednesday after announcing that the company is on track to receive two new patents in the U.S. and EU covering its ...
Aurinia Pharmaceuticals ( NASDAQ: AUPH) has been on a roll this year since their second quarter earnings in August. The stock jumped from $10 to over $30, buoyed by strong uptake of voclosporin ...
The latest price target for Aurinia Pharmaceuticals ( NASDAQ: AUPH) was reported by HC Wainwright & Co. on Friday, September 22, 2023. The analyst firm set a price target for 15.00 expecting AUPH ...
In trading on Thursday, shares of Aurinia Pharmaceuticals Inc (Symbol: AUPH) crossed above their 200 day moving average of $8.57, changing hands as high as $8.92 per share. Aurinia Pharmaceuticals ...Nov 29, 2023 · AUPH | Complete Aurinia Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares are trading higher, adding to gains of more than 17% over the last week. The stock has been trending higher since the company announced that its ...Ocular Therapeutix Inc (NASDAQ:OCUL) has a beta value of 0.88 and has seen 1.29 million shares traded in the recent trading session. The company, currently valued at $262.48M, closed the recent trade at $3.31 per share which meant it gained $0.63 on the day or 23.32% during that session. ... (NASDAQ:AUPH) has a beta value of 1.39 and …Nasdaq Insider Activity page provides trading information of corporate insiders (officers, directors and any beneficial owners of more than 10% of a class of the company’s equity securities). An ...Shares of NASDAQ:AUPH opened at $9.06 on Friday. The company has a market cap of $1.30 billion, a P/E ratio of -17.09 and a beta of 1.25. The company has a debt-to-equity ratio of 0.18, a current ...Aurinia Pharmaceuticals AUPH shares ended the last trading session 5.7% higher at $9.68. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...The public float for AUPH is 130.54M, and at present, short sellers hold a 13.23% of that float. The average trading volume of AUPH on November 20, 2023 was 1.70M shares. AUPH) stock’s latest price update. Aurinia Pharmaceuticals Inc (NASDAQ: AUPH)’s stock price has increased by 3.08 compared to its previous closing price of 8.60.Swiss National Bank raised its holdings in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Free Report) (TSE:AUP) by 7.1% during the second quarter, …Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that the Company's collaboration partner, Otsuka Pharmaceutical Ltd., filed a new drug application (NDA) for ...July 15, 2020 at 10:15 AM · 4 min read. Steven Cohen ( Trades, Portfolio ), head of Point72 Asset Management, disclosed this week his firm upped its stake in Otonomy Inc. (NASDAQ:OTIC) by 1,354. ...
Nov 29, 2023 · The average twelve-month price prediction for Aurinia Pharmaceuticals is $14.00 with a high price target of $15.00 and a low price target of $13.00. Learn more on AUPH's analyst rating history. Do Wall Street analysts like Aurinia Pharmaceuticals more than its competitors? The fact that multiple Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongst investors. When ...Sep 29, 2022 · Anyone who held Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) over the last year knows what a loser feels like. The share price has slid 66% in that time. The share price has slid 66% in that time. Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancinInstagram:https://instagram. tms stockcigna discount planbrokers using mt4best wiskey Aurinia Pharmaceuticals (NASDAQ:AUPH) has been subject to buyout speculations for well over a year now. It was as early as May 2021, when The Times mentioned AstraZeneca ( AZN ) or GSK ( GSK ) are ...Market Capitalization. $1.24 billion. P/E Ratio. N/A. Dividend Yield. N/A. Price Target. $14.00. Stock Analysis Analyst Forecasts Chart Competitors Earnings Financials Headlines Insider Trades Options Chain Ownership SEC Filings Short Interest Social Media. ge investorssandp 500 energy AUPH Stock Overview. Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. About the company. AUPH fundamental analysis. are indian head nickels worth anything NEW YORK, June 03, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...NASDAQ: AKRO. Public. Acquired. Seed deal. NASDAQ: ALXO ... NASDAQ: AUPH. Public. Acquired. Seed deal. NASDAQ: CMPI.Hedge fund activity in Capitol Federal Financial, Inc. (NASDAQ:CFFN) Heading into the second quarter of 2020, a total of 11 of the hedge funds tracked by Insider Monkey held long positions in this ...